CD8A and metastatic melanoma: Using this strategy, we determined the presence of CD8+ T cells recognizing mutation-derived neoepitopes, here denoted as neoantigen-reactive T cells (NARTs), in TIL Inf products from 26 patients with metastatic melanoma.